In the Cartitude 1 trial, the strongest predictor of long-term remission with Siltacel was a lower burden of disease (measured by bone marrow percentage and soluble BCMA levels), rather than the number of prior treatments. This implies using CAR-T therapy earlier in the disease course is more effective.
Using a BCMA bispecific antibody first can exhaust a patient's T-cells or cause tumors to lose the BCMA target, rendering a subsequent BCMA-targeted CAR-T therapy ineffective. The optimal sequence is CAR-T first, which preserves T-cell function and BCMA expression, leaving bispecifics as a viable later-line option.
Surprisingly, patients with high-risk cytogenetics, a typically poor prognostic factor in multiple myeloma, were equally represented in both the long-term remission group and the group that progressed after Siltacel treatment. This suggests CAR-T therapy may overcome traditional risk stratification.
The efficacy of Siltacel stems from a powerful initial expansion that eliminates cancer upfront. The CAR-T cells are often undetectable beyond six months, indicating their curative potential comes from an overwhelming initial response rather than persistent, long-term immune policing of the disease.
The success of CAR-T therapy hinges on the quality of the patient's own lymphocytes. Procuring T-cells earlier in the disease course, before they become exhausted from numerous prior therapies, results in a higher proportion of naive T-cells, leading to better CAR-T cell manufacturing and clinical outcomes.
The term "functional cure" is misleading and hinders progress. With one-third of heavily pretreated patients in the Cartitude 1 trial remaining disease-free for five years without maintenance, the data supports the classical definition of a "cure" used in other cancers. This semantic shift is crucial for advancing the field.